Concurrently, S&P assigned its “AA-” rating to HMH’s proposed $300 million series 2018 bonds.
The upgrade and assignment are based on several factors, including HMH’s large size, which leads to a wide range of clinical services, stable financial performance and solid strategic plans. S&P also acknowledged the health system’s future risks as it opens its medical school and completes its capital spending program.
The outlook is stable, reflecting the health system’s depth of clinical services and operations.
More articles on healthcare finance:
Highmark Health gifts Penn State Health $25M as part of $1B partnership
7 latest hospital credit downgrades
12 hospitals seeking RCM talent
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
